Cardiovascular Disease in Annandale, VA
10 verified cardiovascular disease doctors in Annandale.
Cardiologists diagnose and treat conditions of the heart and blood vessels, including heart disease, arrhythmias, and heart failure.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Albert Kim, MD
Cardiovascular Disease
CMS Open Payments· $577.03 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$577.03
Total received
27
Transactions
8
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 66th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Albert Kim do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Thien Do, MD
Cardiovascular Disease
CMS Open Payments· $418.43 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$418.43
Total received
16
Transactions
5
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 61th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Thien Do do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Merdod Ghafouri, DO
Cardiovascular Disease
CMS Open Payments· $31,282 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$31,282
Total received
34
Transactions
15
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is higher than 94% of that group — among the highest recipients.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Merdod Ghafouri do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Nicholas Balaji, MD
Cardiovascular Disease
CMS Open Payments· $76.66 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$76.66
Total received
1
Transactions
1
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is on the lower end — around the 44th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Nicholas Balaji do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Felix Castro, MD
Cardiovascular Disease
CMS Open Payments· $126.00 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$126.00
Total received
1
Transactions
1
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is on the lower end — around the 47th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Felix Castro do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Paul O'Brien, MD
Cardiovascular Disease
CMS Open Payments· $1,068 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$1,068
Total received
52
Transactions
16
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 74th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Paul O'Brien do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Laurance Kam, MD
Cardiovascular Disease
CMS Open Payments· $1,214 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$1,214
Total received
58
Transactions
17
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 76th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Laurance Kam do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Robert Matthews, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Joel Nadler, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Manisha Reddy, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.